Synonyms: TNG-462 | TNG462
Compound class:
Synthetic organic
Comment: TNG-462 (Tango Therapuetics) is a MTA-cooperative protein arginine methyltransferases 5 (PRMT5) inhibitor, that is proposed to treat methylthioadenosine phosphorylase (MTAP) deleted solid tumours. MTAP deficient cancer cells are unable to obtain adenine and methionine from the salvage pathway [1]. Adding inhibition of PRMT5 further decreases the viability of MTAP deficient cancer cells [2]. The chemical structure shown here was revealed during the First Time Disclosures session at the ACS meeting in September 2023, and we picked it up from Drug Hunter.
The chemical structure of TNG-462 is identical to that for the INN vopimetostat (proposed list 132, Feb. 2025). |
|
No information available. |
Summary of Clinical Use ![]() |
TNG-462 is in clinical development. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/Phase 2 Interventional | Tango Therapeutics, Inc. |